Jefferies raised the firm’s price target on ImmunityBio (IBRX) to $9 from $8 and keeps a Buy rating on the shares. The firm believes ImmunityBio is in execution mode to continue expanding the ...

XmAb819 demonstrated a manageable safety profile with primarily grade 1 or 2 cytokine release syndrome and no neurotoxicity in ccRCC patients. The trial involved 69 patients, with a 25% objective ...

P4 lets networks finally break free of rigid hardware, adding custom protocols, real-time visibility and smarter security ...

LONDON, Dec 11 (Reuters) - Central banks in big economies are signaling a change ‌of ​stance, with many now on hold after a ...

Key delayed U.S. data on jobs and inflation will be closely watched as investors gauge how much further the Federal Reserve ...

Event displays (particle collisions) captured by the detectors of the LHC's four large experiments during 2025. Top left: ...

While the US Federal Reserve’s final interest rate meeting this year could see an unusual amount of division, financial ...

Expressing satisfaction over his regime''s achievements in past 2 years, Rajasthan Chief Minister Bhajan Lal Sharma today said that 70 percent of promises (sankalps) made by the ruling BJP in its ...

The attack forced many town departments to temporarily go analog and find "creative" ways to keep town government functioning ...

Alphabet Inc. (NASDAQ:GOOGL) is one of the AI Stocks Analysts are Tracking Closely. On December 3, Cantor Fitzgerald analyst ...

UnitedHealth Group is far from the perfect stock, but it is an appealing buy because it can learn from its errors and ...

While the US Federal Reserve's final interest rate meeting this year could see an unusual amount of division, financial ...